In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Checkpoint Therapeutics (CKPT – Research Report), with a price target of $26.00. The company’s shares closed last Thursday at $1.09, close to its 52-week low of $0.96.
According to TipRanks.com, Pantginis is ranked 0 out of 5 stars with an average return of -34.8% and a 10.5% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Lineage Cell Therapeutics, and Actinium Pharmaceuticals.
Checkpoint Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $26.00.
See the top stocks recommended by analysts >>
The company has a one-year high of $4.64 and a one-year low of $0.96. Currently, Checkpoint Therapeutics has an average volume of 888.2K.
Based on the recent corporate insider activity of 11 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of CKPT in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Checkpoint Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. Its product portfolio include CK-301, CK-101, CK-103, and CK-302. The company was founded on November 10, 2014 and is headquartered in New York, NY.
Read More on CKPT:
- H.C. Wainwright Thinks X4 Pharmaceuticals’ Stock is Going to Recover
- Analyst Explains Why They Downgraded Their Rating on Pulse Biosciences (PLSE)
- H.C. Wainwright Thinks Wave Life Sciences’ Stock is Going to Recover
- H.C. Wainwright Thinks OpGen’s Stock is Going to Recover
- H.C. Wainwright Thinks Matinas BioPharma’s Stock is Going to Recover
